Updated:
Picard Medical
Picard Medical family office controls SynCardia, the only FDA-approved total artificial heart maker. Publicly traded since August 2025.
Picard Medical
Picard Medical did not disclose its founding year or named principals in public filings. The firm operates as the parent company of SynCardia Systems, which was founded in 2001 by Dr. Jack Copeland, Richard Smith, and Dr. Marvin Slepian. Picard Medical became a publicly traded entity on August 29, 2025, listing on the New York Stock Exchange under the ticker PMI. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (STAH), the only commercially available total artificial heart approved by the FDA and Health Canada. The device builds on the Jarvik-7 design and has been implanted in more than 2,100 patients across 27 countries. The company is developing the fully implantable Emperor System to eliminate external drivers. Its geographic footprint includes the United States and Canada, with clinical use in 27 countries globally. Picard Medical employs an undisclosed number of professionals from its Palo Alto headquarters. No additional offices, philanthropic foundations, or adjacent investment vehicles are publicly listed. The firm's recent operational milestone was its August 2025 IPO on the NYSE. The firm's structural differentiator is its dual identity as a single-family office that controls a publicly traded medical-device company. This arrangement blends family-office governance with public-market disclosure and capital access, a rare architecture in the medtech space.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Palo Alto
Corporate office
Palo Alto, CA, United States
Sector focus
Frequently asked questions
Who controls investment decisions at Picard Medical?
Picard Medical has not publicly identified its named principals or investment committee. As a publicly traded company, governance follows standard corporate structures, but the family office's specific decision-making chain for alternative investments is not disclosed.
What is the relationship between Picard Medical and SynCardia Systems?
Picard Medical is the parent company and wholly owns SynCardia Systems. SynCardia operates as the sole operating subsidiary, focusing on total artificial heart technology. Picard Medical is publicly traded (NYSE: PMI) and serves as the investment vehicle for the Picard family.
Does Picard Medical invest externally or only through its operating company?
Public filings focus on SynCardia's medtech operations. No external investment mandates, fund commitments, or co-investments have been disclosed. The firm appears to concentrate capital within its wholly owned medical-device subsidiary.
What investment stages does Picard Medical target?
Picard Medical's public disclosures center on commercial-stage medical devices. SynCardia's STAH is FDA-approved and commercially available, with the company also developing a next-generation fully implantable system (Emperor System). No early-stage or venture-stage activity has been disclosed.
Where does the underlying wealth of Picard Medical come from?
The source of the Picard family's wealth has not been publicly disclosed. The firm's structure as a public company limits visibility into the family's original capital base.
Is Picard Medical structured as a single family office or a multi-family office?
Based on available public filings, Picard Medical operates as a single-family office structure, controlling a single operating company. No evidence suggests it manages capital for outside families.
Does Picard Medical maintain philanthropic structures?
No philanthropic foundations or charitable arms have been publicly linked to Picard Medical. The firm's disclosures focus entirely on its medtech business operations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: